Announcement • Jun 15
Zelira Therapeutics Limited announced that it expects to receive $0.1 million in funding Zelira Therapeutics Limited has announced a private placement of 20% Unsecured Convertible Loan Note for gross proceeds of $100,000 on June 15, 2026. The loan note will be convertible into shares at the conversion price of $0.2812 per share. This represents an over 20% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Osagie Imasogie and who is the Non-Executive Chairman. The interest payment is 20% per annum paid monthly in cash and the maturity date is June 15, 2027. The company announced that it has obtained approval from board of directors and subject to the approval of shareholders. Announcement • Mar 10
Zelira Therapeutics Limited announced that it expects to receive AUD 0.05 million in funding Zelira Therapeutics Limited has announced a private placement of Loan Note for AUD 50,000 on March 10, 2026. The loan note will be convertible into shares at the higher of AUD 0.58 conversion price. This represents an over 14.7% premium to the closing price on 27 February 2026 and a 1.1% premium to the 15-day VWAP. The transaction involves the investor participation of Mr Tim Slate and who is the Non-exicutive Director. The interest payment is 20% per annum paid monthly in cash and the maturity date is March 10, 2027.The transaction is subject to the approval of shareholders. Announcement • Sep 24
Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025 Zelira Therapeutics Limited, Annual General Meeting, Nov 19, 2025. Announcement • Sep 17
Zelira Therapeutics Limited announced that it expects to receive $0.15 million in funding Zelira Therapeutics Limited has announced a private placement on September 16, 2025, of USD 150,000 of loan note which will become convertible into shares at the higher of USD$0.2585 and the 15-day VWAP prior Zelira electing to convert. The Loan Notes are are being executed by Oludare Odumosu and r Donna Gentile O’Donnell of f USD$100,000 and USD$50,000 respectively, on attractive terms. The interest payment is 20% per annum paid monthly in cash and the maturity date is September 16, 2026. Reported Earnings • Aug 31
Full year 2025 earnings released Full year 2025 results: Net loss: AU$3.63m (loss narrowed 90% from FY 2024). New Risk • Feb 27
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$5.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.3m free cash flow). Negative equity (-AU$8.0m). Earnings have declined by 31% per year over the past 5 years. Revenue is less than US$1m (AU$41k revenue, or US$26k). Market cap is less than US$10m (AU$5.67m market cap, or US$3.57m). Announcement • Sep 12
Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024 Zelira Therapeutics Limited, Annual General Meeting, Nov 14, 2024. Reported Earnings • Aug 29
Full year 2024 earnings released Full year 2024 results: Net loss: AU$36.6m (loss widened AU$31.0m from FY 2023). Announcement • Jul 05
Zelira Therapeutics Limited announced that it has received $1.4 million in funding On July 4, 2024, Zelira Therapeutics Limited closed the transaction. New Risk • Feb 24
New major risk - Negative shareholders equity The company has negative equity. Total equity: -AU$2.0m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.4m free cash flow). Negative equity (-AU$2.0m). Earnings have declined by 35% per year over the past 5 years. Revenue is less than US$1m (AU$279k revenue, or US$183k). Market cap is less than US$10m (AU$9.65m market cap, or US$6.33m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). Reported Earnings • Oct 05
Full year 2023 earnings released: AU$0.55 loss per share (vs AU$1.49 loss in FY 2022) Full year 2023 results: AU$0.55 loss per share (improved from AU$1.49 loss in FY 2022). Net loss: AU$5.57m (loss narrowed 53% from FY 2022). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings. Announcement • Sep 15
Zelira Therapeutics Limited, Annual General Meeting, Nov 15, 2023 Zelira Therapeutics Limited, Annual General Meeting, Nov 15, 2023. Agenda: To consider the re-election of Directors. Reported Earnings • Sep 01
Full year 2023 earnings released Full year 2023 results: Net loss: AU$5.57m (loss narrowed 53% from FY 2022). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. New Risk • Aug 31
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (AU$890k revenue, or US$576k). Market cap is less than US$10m (AU$12.5m market cap, or US$8.09m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (18% increase in shares outstanding). New Risk • Aug 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$15.4m (US$9.88m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (66% average weekly change). Earnings have declined by 34% per year over the past 5 years. Revenue is less than US$1m (AU$890k revenue, or US$570k). Market cap is less than US$10m (AU$15.4m market cap, or US$9.88m). Minor Risk Shareholders have been diluted in the past year (18% increase in shares outstanding). Announcement • May 31
Zelira Therapeutics Limited Announces Board Changes Zelira Therapeutics Ltd. announced it has appointed Dr. Donna Gentile O'Donnell as non-executive director, effective 1 June 2023. Dr. O'Donnell served as Special Assistant to the President, Dr. Stephen K. Klasko, and is Senior Vice President for Innovation Partnerships and Programs at Thomas Jefferson University. Donna has led a diverse and successful career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organisations, universities, and life science companies, including Cephalon Pharmaceuticals. She was previously the managing director of the Eastern Technology Council for nine years. There, she played a significant role in developing and creating BioAdvance, a state entity designed to grow the life sciences industry in Southeastern Pennsylvania, as well as many other key life science initiatives. She was a special limited partner in PA Early Stage Partners. As former president of Franklin Health Trust, Dr. O'Donnell was instrumental in leading the negotiations for the merger of $50 million of the foundation's assets into the Drexel University College of Medicine. She served as Deputy Health Commissioner for Policy and Planning in the City of Philadelphia in the mid-1990s under former Mayor Ed Rendell. During that time she wrote the only successful competitive federal health care grant in the Summer of Service program, to increase the rate of immunisation for at-risk children, newborn to 2 years old and received the Clara Barton Humanitarian Award from the Southeastern Pennsylvania Chapter of the American Red Cross. In 2020, she was elected as a Fellow to the Philadelphia College of Physicians. In 2005, she was awarded Philadelphia Business Journal's Women of Distinction Award. In 2017, Gov. Tom Wolf appointed her to the Health Research Advisory Committee, which oversees the Commonwealth Universal Research Enhancement Program, or CURE. The CURE program, administered by the Pennsylvania Department of Health, advises on the distribution of 19% of the $11 billion tobacco settlement that goes to health and life-science-related research. In addition, Dr. O'Donnell served on the Women's Financial Services Network Advisory Board for PNC Bank and has served on the Regional Editorial Board of ADVANCE For Nurses. Furthermore, the company that Ms. Lisa Gray has resigned from the position of Non-Executive Director effective 31 May 2023, to focus on her other business interests and directorships. The board is wholeheartedly grateful to Ms. Gray for her significant contribution to the company as one of its founding Directors and wish her all the best with her future endeavours. Ms. Gray remains a shareholder in Zelira. Announcement • May 22
Zelira Therapeutics Limited announced that it expects to receive $22 million in funding Zelira Therapeutics Limited announced a private placement for the gross proceeds of $22 million on May 22, 2023. The company has raised $35 million in total funding till date. Reported Earnings • Mar 03
First half 2023 earnings released: AU$0.38 loss per share (vs AU$0.81 loss in 1H 2022) First half 2023 results: AU$0.38 loss per share (improved from AU$0.81 loss in 1H 2022). Net loss: AU$3.28m (loss narrowed 38% from 1H 2022). Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Announcement • Feb 20
Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive Director Zelira Therapeutics Limited announced Mr. Greg Blake has been promoted from VP - Global Head of Commercial and Partnering to Executive Director effective 20 February 2023. Mr. Blake has been employed by Zelira since 2020. Greg brings extensive commercial and operational leadership experience in the pharmaceutical and biotech sectors both within Australia and internationally. Greg has led the strategic development and commercialisation of a number of products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a solid foundation of knowledge across marketing and the entire commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch critical pathway and commercialisation planning for both domestic and international markets. As Marketing Lead (Europe) with Mundipharma International, Greg successfully led 26 European countries through the pre-launch and launch phases for a novel pain medication.Greg has held leadership roles at large multinationals (J&J and CSL) and publicly-listed biotech start-ups. Board Change • Nov 16
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 7 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). Member of Medical Advisory Board Joe Goldstrich is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Announcement • Sep 22
Zelira Therapeutics Limited, Annual General Meeting, Nov 17, 2022 Zelira Therapeutics Limited, Annual General Meeting, Nov 17, 2022. Agenda: Annual General Meeting. Announcement • Sep 21
Zelira Therapeutics Launches ZYRAYDI™ B2b Technology to Create Pharma-Grade Cannabis Capsules & Tablets for Global Markets Zelira Therapeutics Limited announce the launch of ZYRAYDI™, its patented, licensable technology for the future of the medical cannabis industry. ZYRAYDI™ is a proprietary Enhanced Distillate Capture and Dissolution Matrix technology that substantially traps the distillate in a free flow powder matrix and increases the rate of dissolution. With ZYRAYDI™, Zelira Therapeutics continues to create new, innovative ways to produce pharmaceutical-grade cannabinoid oral dosage forms like capsules and tablets. Designed to be a valuable tool for the cannabinoid producers around the world, ZYRAYDI™ requires minimal capital expenditure on equipment and raw materials and is immediately adaptable to any existing capsule and tablet program. The ZYRAYDI matrix contains pharmaceutical grade excipients that are on the FDA-approved list of GRAS (Generally Recognized As Safe) ingredients, and can be adapted to fit requirements for vegan, gluten free, allergen free, non-GMO, etc. Announcement • Sep 15
Zelira Therapeutics Limited Completes Two-Thirds of Enrolment for Diabetic Nerve Pain Drug Trial Zelira Therapeutics Ltd. announced the successful enrolment of 40 out of 60 patients in the clinical trial for diabetic nerve pain, announced 12 July 2021. The trial was designed and approved as a multi-arm, head-to-head trial against a major Big Pharmaceutical company's multi-billion dollar revenue drug, using Zelira's proprietary, patent protected product. The trial is powered to show statistical significance with 60 subjects (20 subjects in each arm). In May 2022, Zelira announced the complete enrolment of 20 patients in arm 1, being the investigative drug arm of the trial. An additional 20 subjects currently using the Big Pharmaceutical company drug, have been successfully enrolled. The second arm will serve as an active reference arm for thetrial, with the trial designed where the third arm will evaluate the synergistic effect (combined effects) of the reference drug.Zelira expects to complete trial enrolment and provide a trial read out in fourth quarter of 2022. Reported Earnings • Sep 01
Full year 2022 earnings released: AU$1.54 loss per share (vs AU$1.29 loss in FY 2021) Full year 2022 results: AU$1.54 loss per share (down from AU$1.29 loss in FY 2021). Net loss: AU$11.9m (loss widened 40% from FY 2021). Over the next year, revenue is forecast to grow 275%, compared to a 657% growth forecast for the Pharmaceuticals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Announcement • Jul 22
Zelira's Zenivol™, the First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany Zelira Therapeutics Ltd. announced that its insomnia medication Zenivol™ has achieved formal approval from German regulatory authority BfArM to launch in the German medical cannabis market. Zenivol™ is the first and only clinically validated, pharmaceutical-grade, cannabis-based sleep medication. Zenivol™'s clinical research achieved the higher level of scientific review when it was peer reviewed in the Journal of Sleep. It is currently available by prescription in Australia under the country's legal cannabis regulations. Announcement • Jun 10
Zelira Therapeutics Ltd Publishes White Paper Detailing the Analysis of Longitudinal, Real-World Data Generated from Patients Using ZENIVOL Zelira Therapeutics Ltd. announced that it has published a white paper detailing the analysis of longitudinal, real-world data (RWD) generated from patients using ZENIVOL®. The agreement between Zelira Therapeutics and Emyria Ltd. (ASX:EMD) was to collect longitudinal, real world data for patients diagnosed with chronic insomnia who were treated with Zelira's ZENIVOL® product including de-identified patient data relating to diagnosis and co-morbidities, concomitant medications, dosages prescribed to patients and the ef ectiveness of ZENIVOL® using various clinical and subjective endpoints including the Insomnia Severity Index (ISI) questionnaire. The longitudinal, real-world data (RWD) of 94 patients was generated from two data sources: Dispensing data obtained as part of Zelira's regulatory obligations and Zelira sponsored observational trial conducted by Emyria's Emerald Clinics (n = 42). The results published in a white paper are available on Zelira's website her e. A summary of the key findings include: Mean age of patients on ZENIVOL® was 54 years of age; the youngest and oldest patient were 6 and 78 years of age respectively. A substantial proportion of active ZENIVOL® patients were over the age of 65 suggesting that in the short to medium term, ZENIVOL® is safe and ef ective in this cohort. Mean time on ZENIVOL® was 4.3 months; maximum treatment time to-date was 10.8 months. The primary indications of patients receiving ZENIVOL® was Chronic non-cancer pain (44%), Insomnia (36%) and post-traumatic stress disorder (12%). The Emerald Clinics ZENIVOL® patients, most reported being on a concomitant medication for pain relief ranging from opioids (i.e., oxycodone, codeine, tramadol), to benzodiazepines (diazepam) to over-the-counter pain relief medications (i.e., paracetamol, ibuprofen). ZENIVOL® appears to be ef ective: Overall, patients had a mean baseline ISI score of 19.5 (Moderate clinical insomnia), however after taking ZENIVOL® the mean ISI score significantly reduced to 14.3 (Subthreshold insomnia levels) (p<0.001). At baseline, 15 patients were rated as having Severe clinical insomnia. After being on ZENIVOL®, 33% of these patients had reduced their ISI score to Moderate clinical insomnia levels, and 40% had reduced to Subthreshold insomnia levels. No improvement in the ISI score was seen in 27% of the Severe clinical insomnia patients. At baseline, nine (9) patients were rated as having Moderate clinical insomnia. After being on ZENIVOL®, a third saw no improvement in their insomnia, whilst 44% reduced their ISI score to Subthreshold insomnia levels and 22% achieved ISI scores that rated them as having No clinically significant insomnia. For those patients with Subthreshold insomnia at baseline, 20% were able to reduce their ISI scores to No clinically significant insomnia, with the remainder maintaining a Subthreshold insomnia rating. Announcement • May 13
Zelira Therapeutics Ltd Announces Resignation of Harry Karelis as Non-Executive Vice Chairman Zelira Therapeutics Ltd. announced that Mr. Harry Karelis has resigned from the position of Non-Executive Vice Chairman effective 12 May 2022. Announcement • May 10
Zelira Therapeutics Limited Successfully Launches ITURA with CVSCM Zelira Therapeutics Ltd. announced the launch of a new product ITURA - Advanced Relief Cream Formula through its partnership with Cardiovascular Solutions of Central Mississippi (CVSCM). ITURA is an advanced relief cream formula using CBD and Hemp Spectra Technology that targets multi-symptoms such as numbness and tingling, muscle cramps, insensitivities and neuropathies including pain associated with Peripheral Artery Disease and diabetes. Board Change • Apr 28
No independent directors There are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 8 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Member of Medical Advisory Board Joe Goldstrich is the most experienced director on the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Announcement • Jan 31
Zelira Therapeutics Limited Appoints Timothy Slate as Director Zelira Therapeutics Limited appointed Timothy Slate as director. Date of appointment is 31 January 2022. Mr. Tim Slate was appointed as Company Secretary on 16 December 2016. Mr. Slate provides accounting, secretarial and corporate advice to a number of private and public companies. Mr. Slate has over 15 years' experience. Mr. Slate has a Bachelor of Commerce from the University of Western Australia, is a Chartered Accountant, is an Associate Member of the Governance Institute of Australia and is a Graduate of the Australian Institute of Company Directors. Announcement • Sep 24
Zelira Therapeutics Limited Launches RAF FIVE Acne Treatment Products Zelira Therapeutics Ltd. announced the US launch of the Zelira Dermatology Business' first product line, RAF FIVETM through its dermatology subsidiary Ilera Derm LLC (Zelira Dermatology). The five-product RAF FIVETM line consists of the Wash Away Gel Cleanser Acne Treatment, Spot On Acne Treatment, Kick Off Hydrating Lotion Broad Spectrum SPF 30 Sunscreen, After Hours Moisturizing Lotion Acne Treatment, and Clear the Way Acne Treatment Pads. The products include known skin-boosting ingredients hyaluronic acid, niacinamide, glycerin, thiotaine (derived from mushrooms), and peptides. The RAF FIVETM line is Zelira's first step into the acne medication market valued at more than US$11 billion worldwide. Available now in the United States at www.raffive.com, RAF FIVETM is the skin care line in the world to feature Zylorma®, a patent-pending acne fighting complex developed by Zelira and US board-certified cosmetic dermatologist Dr. Karyn Grossman. Zylorma® uses a proprietary formulation with CBD, salicylic acid and additional botanical compounds to fight bacteria and clogged pores associated with acne, and balance sebum production to help eliminate and prevent acne breakouts. The results from RAF FIVE'sTM 28-day self-assessment survey of 45 participants showed significant improvements in the individuals using RAF FIVETM treatments. Zelira also conducted a rigorous industry standard consumer use study for its RAF FIVETM franchise that showed improvement in all of the participants during the 28 day study. Results showed significant improvement as early as 7 days for some of the participants. Announcement • Jul 14
Zelira Therapeutics Ltd Obtains IRB Approval for US Observational Clinical Pain Trial Zelira Therapeutics Ltd. announced that it has obtained IRB approval for its 12 week Observational Clinical Study to evaluate the efficacy, safety and tolerability of its proprietary, patent protected product against a multi-billion dollar Big Pharmaceutical company drug. Zelira has successfully navigated a unique regulatory path for this trial and looks forward to the results of the study, which is anticipated to be available in the first half of 2022. Zelira continues to lead the world in creating and validating proprietary products such as Zenivol®, with a focus on taking these drugs through regulatory registration. Announcement • Jun 22
Zelira Therapeutics Ltd. Announces Clinical Trial Results of Zelira's Zenivol Published in the Prestigiouspeer-Reviewed Journal Sleep Zelira Therapeutics Ltd. announced that the University of Western Australia's investigational team that undertook the double-blind, placebo controlled, cross-over trial of Zelira's ZTL-101 (on market as Zenivol) in chronic insomnia patients has had the results of its trial published in the peer-reviewed journal SLEEP. As outlined in the manuscript, chronic insomnia is present in between 6-15% of the population and is
associated with adverse health outcomes. Current pharmacological treatment options are often
unsatisfactory with significant side effects. The published results demonstrated that following 2-weeks of
using Zelira's ZTL-101, patients saw a significant decrease in insomnia symptoms relative to placebo. Announcement • Jun 18
Zelira Therapeutics Limited Researchers Develops New Technology to Improves Delivery of CBD into Brain Zelira Therapeutics Limited announced that a Zelira-funded team of researchers at Curtin University (Australia) have developed a new technology that improves delivery of cannabidiol (CBD) based drugs into the brains of mice by up to 40-times. This technology has potential for cannabinoid-based therapies to treat neurological disorders such as Alzheimer's disease, multiple sclerosis, and traumatic brain injury. Published in the leading peer reviewed open access scientific journal PLOS ONE, the Curtin University research team created tiny capsules containing cannabinoids which, when taken orally, were absorbed by the body faster and penetrated the brain quicker in mice models with neurological diseases, than when delivered in liquid form. This research was a collaborative effort involving researchers from CHIRI, the Curtin Medical School and the School of Population Health at Curtin University, the University of Newcastle and the University of Otago. Executive Departure • May 18
MD & Director has left the company On the 15th of May, Richard Hopkins' tenure as MD & Director ended after 2.8 years in the role. As of December 2020, Richard personally held 1.70m shares (AU$156k worth at the time). Richard is the only executive to leave the company over the last 12 months. Announcement • Dec 16
Zelira Therapeutics Ltd Announces to Enter into A Binding Licensing Agreement with Alternative Solutions LLC Zelira Therapeutics Ltd. announced that it has entered into a binding licensing agreement with Alternative Solutions LLC. Under the terms of the licensing agreement, Zelira will receive an upfront fee and ongoing royalties from HOPETM product sales in Washington DC. Washington DC has reciprocity with 32 other states in the USA with approved medical cannabis programs. This expands access to patients registered in all the 32 states as they can legally purchase medical cannabis products at an approved dispensary in Washington DC. Zelira previously licensed HOPETM in Pennsylvania to Ilera Healthcare LLC which holds the license for that State and in Louisiana to Advanced Biomedics LLC. Zelira remains focussed on expanding the distribution of HOPETM through licensing agreements in each approved market across the USA next year, as the COVID- 19 pandemic gets under control. Announcement • Dec 04
ZLD Partners with SprinJene to Launch CBD Toothpaste in US Zelira Therapeutics Ltd. announce the launch of its proprietary CBD toothpaste in the United States of America (USA). The CBD toothpaste is a proprietary formulation developed by Zelira and SprinJene's® CEO and Founder Dr. Sayed Ibrahim. The product is the first of several scientifically formulated, hemp-derived, oral care products containing cannabinoids, including broad-spectrum CBD, that will be created and launched under the Zelira Oral Care subsidiary that has partnered with the SprinJene® brand as announced in September (www.zeliraoralcare.com). Research shows that incorporating CBD into oral/dental care results in health benefits including naturally eliminating decay-causing bacteria, reducing gum inflammation, restoring pH balance and increasing remineralisation, reducing bone loss associated with gum disease, and helping to improve overall health. The Zelira-SprinJene® CBD Toothpaste uses broad-spectrum, THC-free CBD distillate derived from hemp. This provides Zelira-SprinJene® users with the full benefits of a wide array of cannabinoids, with no psychoactive effects. The Zelira-SprinJene® CBD product will be distributed in the USA through SprinJene's® existing distribution channels including retail stores such as Bed Bath & Beyond, Central Market, Sprouts, Lassen's, Haggens, and VitaCos and e-commerce platforms such as Amazon. Discussions are ongoing to access SprinJene's® global distribution networks in France, Russia, UK, Singapore, Ukraine, China, Morocco, United Arab Emirates, Saudi Arabia and Sudan Shoprite. Announcement • Sep 24
Zelira Therapeutics Limited announced that it expects to receive AUD 1.999998 million in funding from Thorney Investment Group Australia Pty. Ltd. Zelira Therapeutics Limited (ASX:ZLD) announced a private placement of 37,037,000 shares at a price of AUD 0.054 per share for gross proceeds of AUD 1,999,998 on September 23, 2020. The transaction will include participation from new investor Thorney Investment Group Australia Pty. Ltd. Post to the closing, the investor will acquire 5.2% stake in the company. The transaction is subject to shareholder approval at annual general meeting in November, the company will issue a one-for-one free attaching unquoted option, exercisable at AUD 0.07 and expiring two years from the date of issue. Announcement • Sep 17
Zelira Therapeutics Ltd. Announces Zenivol Launches in Australia After TGA Approves Release Zelira Therapeutics Ltd. announced that its proprietary cannabinoid medicine ZenivolTM can now be prescribed to patients in Australia through the Therapeutic Goods Administration's (TGA) Special Access Scheme and via Authorised Prescribers. ZenivolTM is available for immediate supply via Zelira's national distribution partner Health House. Zelira recently successfully completed a world-first; a clinical trial powered to show statistical significance through a randomised, double-blind, cross-over designed Phase 2A clinical study in patients suffering from chronic insomnia treated with ZenivolTM. The results confirmed that ZenivolTM is a safe and effective therapy for chronic insomnia. ZenivolTM treatment significantly improved key insomnia symptoms, as measured using the Insomnia Severity Index (ISI) - a current standard for measuring effectiveness of insomnia treatment, and was not associated with any serious adverse events. This trial was conducted at the world-class University of Western Australia (UWA) Centre for Sleep Science. Analysis of secondary endpoints showed patients treated with ZenivolTM slept longer, went to sleep faster and went back to sleep sooner after waking. Patients also reported statistically significant improvements in quality of life measures including feeling rested after sleep, feeling less stressed, less fatigued and improved overall functioning. Announcement • Aug 15
Zelira Therapeutics Limited announced that it has received AUD 8.749378 million in funding On August 11, 2020, Zelira Therapeutics Limited (ASX:ZLD) closed the transaction. The transaction included participation from sophisticated and professional investors. Announcement • Aug 04
Zelira Therapeutics Limited announced that it expects to receive AUD 8.749378 million in funding Zelira Therapeutics Limited (ASX:ZLD) announced a private placement of 174,987,560 commons shares issued at AUD 0.05 per share for gross proceeds of AUD 8,749,378 on August 3, 2020. The transaction will include participation from new and existing sophisticated investors in Australia and the
United States. The company expects to close the transaction on August 11, 2020. The transaction was approved by the board of directors of the company. 
